Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019.

Ogata, Hiroaki; Nakagawa, Taisuke; Sakoda, Soichiro; Ishimatsu, Akiko; Taguchi, Kazuhito; Kadowaki, Masako; Moriwaki, Atsushi; Yoshida, Makoto

Ogata, Hiroaki; Nakagawa, Taisuke; Sakoda, Soichiro; Ishimatsu, Akiko; Taguchi, Kazuhito; Kadowaki, Masako; Moriwaki, Atsushi; Yoshida, Makoto.

Afiliação

Ogata H; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Nakagawa T; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Sakoda S; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Ishimatsu A; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Taguchi K; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Kadowaki M; Department of Infectious Diseases National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Moriwaki A; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.
Yoshida M; Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.

Respirol Case Rep ; 9(5): e00744, 2021 May.

Article em En | MEDLINE | ID: mdl-33815804

Palavras-chave

Acute respiratory distress syndrome; coronavirus disease 2019; nintedanib; pulmonary fibrosis; severe acute respiratory syndrome coronavirus 2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article